ImClone Systems Incorporated[FrontPage Include Component]
Clinical Trials - BEC2
BEC2 (Mitumomab) is an anti-idiotypic monoclonal antibody designed to prevent or delay the reoccurrence of targeted tumors when used with BCG (Bacillus Calmette Guerin) as an immune stimulant. Mitumomab mimics the GD3 epitope on the surface of these targeted cancers and potentially stimulates the body’s immune system to identify and eliminate the tumor or metastases, prevent reoccurrence, and prolong survival. Targeted tumors expressing the GD3 epitope have been explored in limited pilot studies for patients with small cell lung cancer or melanoma.
Clinical trials of BEC2 currently enrolling patients are as follows:
small cell lung cancer for newly diagnosed patients with limited stage disease who have successfully completed a regimen of first line combined modality therapy. Patients with either a complete or partial response to therapy are randomized to one of two treatments, either standard care alone or standard care plus BEC2 vaccination therapy. The primary objective of this study is to determine the survival benefit of BEC2 vaccination. This multi-center, multi-national study is open to enrollment.
Send mail to firstname.lastname@example.org with questions or comments about these pages.We invite you to take a look at our Album.
www.angelfire.com/sc/molangels/index.html( Very informational, good tips, Molers pictures, art work and much more....